CytoDyn to Hold Webcast to Provide a Company Update
CytoDyn to Hold Webcast to Provide a Company Update
VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Cyrus Arman, President, Antonio Migliarese, Chief Financial Officer, and Scott Hansen, our newly appointed Head of Research and Basic Science, will host an investment community webcast to provide a Company update on Tuesday, April 11, 2023.
華盛頓州溫哥華，2023 年 4 月 5 日（GLOBE NEWSWIRE）——開發具有多種治療適應症的 CCR5 拮抗劑 leronlimab 的生物技術公司 CytoDyn Inc.（OTCQB：CYDY）（“CytoDyn” 或 “公司”）今天宣佈，董事會主席、賽勒斯·阿曼總裁、首席財務官安東尼奧·米利亞雷塞官員和我們新任命的研究與基礎科學主管斯科特·漢森將於2023年4月11日星期二主持投資界網絡直播，介紹公司的最新情況。
Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.
更新後，將在適當的範圍內解決在網絡直播之前提交的問題，如下所示。
| Date: | Tuesday, April 11, 2023 | ||
| Time: | 1:00 pm PT / 4:00 pm ET | ||
| Access: | |||
| Questions: | Please submit any questions prior to the webcast, and not later than Noon PT, Friday, April 7, 2023. Questions can be submitted via email to: ir@cytodyn.com. Per CytoDyn's current policy, the presenters will not be able to take live questions during the webcast. |
| 日期： | 2023年4月11日，星期二 | ||
| 時間： | 太平洋時間下午 1:00 /美國東部時間下午 4:00 | ||
| 訪問權限： | |||
| 問題： | 請在網絡直播之前提交任何問題，不遲於太平洋時間 2023 年 4 月 7 日星期五中午。問題可以通過電子郵件提交至：ir@cytodyn.com。根據CytoDyn目前的政策，主持人將無法在網絡直播期間進行現場提問。 |
This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until May 11, 2023.
這是一場直播演示。鼓勵參與者在活動開始之前儘早登錄。重播將在網絡直播結束後大約 60 分鐘內播出，可通過上面的鏈接訪問，直到 2023 年 5 月 11 日。
CONTACTS
Investors:
Cristina De Leon
Office: 360.980.8524
ir@cytodyn.com
聯繫人
投資者：
克里斯蒂娜·德萊昂
辦公室：360.980.8524
ir@cytodyn.com
譯文內容由第三人軟體翻譯。